ATNM Actinium Pharmaceuticals Inc. (Delaware)

0.70
-0.00  -1%
Previous Close 0.71
Open 0.73
Price To book 6.39
Market Cap 56262465
Shares 80,020,573
Volume 824,911
Short Ratio 3.01
Av. Daily Volume 856,403

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to initiated September 2016. Interim analysis due by end of 2017 with top-line data due 1H 2018.
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 3 initiated June 2016. Enrollment to be completed by the end of 2018. Data due 2H 2019
Iomab-B
Hematopoietic Stem Cells Transplantation

Latest News

  1. Actinium Pharmaceuticals to Present at BIO Investor Forum
  2. Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
  3. Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
  4. Adgero Biopharmaceuticals Appoints Felix T. Garzon, M.D., Ph.D. as Chief Medical Officer
  5. Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
  6. Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
  7. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Actinium Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  8. Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
  9. Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
  10. Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7
  11. Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
  12. Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
  13. Trump can’t ‘let’ Obamacare fail — but he can help destroy it